Sanofi/$SNY

Sanofi falls after Phase III results for experimental inflammation drug amlitelimab underperformed investors’ expectations and lagged its Dupixent benchmark.
11 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Sanofi

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Ticker

$SNY
Sector
Primary listing

Employees

82,878
Headquarters

Sanofi Metrics

BasicAdvanced
$122B
5.83
$8.56
0.41
$1.60
3.20%

What the Analysts think about Sanofi

Analyst ratings (Buy, Hold, Sell) for Sanofi stock.

Bulls say / Bears say

Dupixent sales rose 21.1% to €3.83 billion in Q2, prompting Sanofi to raise its full-year sales growth forecast to high single digits. (Reuters)
The FDA approved Wayrilz (rilzabrutinib) for chronic immune thrombocytopenia in August, marking a successful integration of the Principia Biopharma acquisition and analysts forecast peak sales of $2–5 billion. (Reuters)
Dupixent generated over €1 billion in sales outside the U.S. in Q2 despite price reductions in China, demonstrating resilient international demand. (Reuters)
Quarterly business operating income excluding one-offs grew only 3.3% despite 21.1% sales growth, weighed down by higher R&D spending and profit-sharing with Regeneron. (Reuters)
Sanofi’s reliance on Dupixent, expected to account for over a third of revenue this year, heightens concentration risk if growth slows or biosimilars emerge. (Reuters Breakingviews)
Sanofi’s $9.5 billion acquisition of Blueprint Medicines to reduce Dupixent dependency may strain returns given Blueprint’s current operating losses and competitive threats. (Reuters Breakingviews)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.

Sanofi Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sanofi Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SNY

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs